Acta Vet. Brno 2019, 88: 225-232
https://doi.org/10.2754/avb201988020225
The effect of triamcinolone in liposomes on oral wound healing in rats
References
1. KD, Strempel H, Klein G 1984: Novel concept for a mucosal adhesive ointment. J Pharm Sci 73: 548-552
<https://doi.org/10.1002/jps.2600730429>
2. PA, Thomas GJ, Langdon JD 2003: The role of nitric oxide in oral diseases. Arch Oral Biol 48: 93-100
<https://doi.org/10.1016/S0003-9969(02)00183-8>
3. DE, Touchard F, Pappas NA 1988: Pharmaceutical and medical aspects of bioadhesive systems for drug administration. Drug Dev Ind Pharm 14: 283-318
<https://doi.org/10.3109/03639048809151972>
4. V, Pavlica Z, Sentjurc M, Petelin M 2006: In vivo study of liposomes as drug carriers to oral mucosa using EPR oximetry. Int J Pharm 307: 1-8
<https://doi.org/10.1016/j.ijpharm.2005.09.016>
5. A, Diniz-Freitas M, Gandara-Vila P, Blanco-Carrion A, Garcia-Garcia A, Gandara-Rey J 2006: Triamcinolone acetonide mouth rinses for treatment of erosive oral lichen planus: efficacy and risk of fungal over–infection. Oral Dis 12: 559-565
<https://doi.org/10.1111/j.1601-0825.2006.01238.x>
6. MA 2010: The use of topical corticoids in oral pathology. Med Oral Patol Oral Cir Bucal 15: e827-e8231
<https://doi.org/10.4317/medoral.15.e827>
7. MA, Morales-Garcia P, Rodriguez-Archilla A 2002a: Clobetasol mouthwash is effective for severe oral erosive lesions. Dent Abstr 47: 268
8. MA, Morales P, Rodriguez-Archilla A, Isabel IR, Gonzalez-Moles S 2002b: Treatment of severe chronic oral erosive lesions with clobetasol propionate in aqueous solution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 93: 264-270
<https://doi.org/10.1067/moe.2002.120522>
9. MA, Ruiz-Avila I, Rodriguez-Archilla A, Morales-Garcia P, Mesa-Aguado F, Bascones-Martinez A, Bravo M 2003: Treatment of severe erosive gingival lesions by topical application of clobetasol propionate in custom trays. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95: 688-692
<https://doi.org/10.1067/moe.2003.139>
10. MA, Scully C 2005a: Vesiculo-erosive oral mucosal disease management with topical corticosteroids: (1) fundamental principles and specific agents available. J Dent Res 84: 294-301
<https://doi.org/10.1177/154405910508400401>
11. MA, Scully C 2005b: Vesiculo-erosive oral mucosal disease management with topical corticosteroids: (2) Protocols, monitoring of effects and adverse reactions, and the future. J Dent Res 84: 302-308
<https://doi.org/10.1177/154405910508400402>
12. AD, Socransky SS 1994: Microbial etiological agents of destructive periodontal diseases. Periodontol 2000 5: 78-111
<https://doi.org/10.1111/j.1600-0757.1994.tb00020.x>
13. BB, Hilchie JC, Mezei M 1986. Liposomes as drug carriers for oral ulcers. J Dent Res 65: 1133-1141
<https://doi.org/10.1177/00220345860650090501>
14. N, Koray M, Kocaelli H, Akinci S 2008: iNOS expression in oral and gastrointestinal tract mucosa. Dig Dis Sci 53: 1437-1442
<https://doi.org/10.1007/s10620-007-0061-5>
15. J, Abramovic Z, Sentjurc M 2003: Skin oxygenation after topical application of liposome–entrapped benzyl nicotinate as measured by EPR oximetry in vivo: influence of composition and size. AAPS Pharm Sci 5: 19-27
<https://doi.org/10.1208/ps050102>
16. M, Sentjurc M, Kristl J 2001: Improved skin oxygenation after benzyl nicotinate application in different carriers as measured by EPR oximetry in vivo. J Control Release 70: 203-211
<https://doi.org/10.1016/S0168-3659(00)00351-5>
17. DF, Kjeldsen M, Sander L, Kinane DF 2000: Inducible nitric oxide synthase expression in periodontitis. J Periodontal Res 35: 369-373
<https://doi.org/10.1034/j.1600-0765.2000.035006369.x>
18. Little JW, Miller CS, Rhodus NL, Falace D (Eds) 2002: Dental Management of the Medically Compromised Patient. 6th edn. St. Louis, Mosby.
19. Z, Benedek P, Fehér E, Györfi A, Rosivall L, Fazekas A, Salzman AL, Szabó C 1998: Protective effects of mercaptoethylguanidine, a selective inhibitor of inducible nitric oxide synthase, in ligature–induced periodontitis in the rat. Br J Pharmacol. 123: 353-360. Erratum in: Br J Pharmacol 123: 741
<https://doi.org/10.1038/sj.bjp.0701604>
20. Z, Stachlewitz R, Virag L, Szekely AD, Hasko G, Szabó C 2001: Evidence for reactive nitrogen species formation in the gingivomucosal tissue. J Dent Res 80: 470-475
<https://doi.org/10.1177/00220345010800021401>
21. F, Huang MZ, Zhou GA 1991: Open preliminary clinical trial of clobetasol propionate ointment in adhesive paste for treatment of chronic oral vesiculoerosive diseases. Oral Surg Oral Med Oral Pathol 71: 283-287
<https://doi.org/10.1016/0030-4220(91)90300-2>
22. F, Miranda C 1997: Oral lichen planus: topical and systemic therapy. Semin Cutan Med Surg 16: 295-300
<https://doi.org/10.1016/S1085-5629(97)80019-3>
23. F, Miranda C, Maliksi R 1994: Double-blind clinical trial of 0.05% clobetasol propionate ointment in orabase and 0.05% fluocinonide ointment in orabase in the treatment of patients with oral vesiculoerosive diseases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 77: 598-604
<https://doi.org/10.1016/0030-4220(94)90318-2>
24. F, Silverman S Jr, Migliorati C 1984. Adverse side effects associated with prednisone in the treatment of patients with oral inflammatory ulcerative diseases. J Am Dent Assoc 109: 269-270
<https://doi.org/10.14219/jada.archive.1984.0349>
25. M, Gulasekharam V 1982: Liposomes: a selective drug delivery system for the topical route of administration. Gel dosage form. J Pharm Pharmacol 34: 473-474
<https://doi.org/10.1111/j.2042-7158.1982.tb04767.x>
26. S, Higgs A 1993. The L-arginine-nitric oxide pathway. N Engl J Med 329: 2002-2012
27. JA, Reed BL, Finnin BC 2005: Enhancing the buccal mucosal uptake and retention of triamcinolone acetonide. J Control Release 105: 240-248
<https://doi.org/10.1016/j.jconrel.2005.03.022>
28. M, Sentjurc M, Stolic Z, Skaleric U 1998: EPR study of mucoadhesive ointments for delivery of liposomes into the oral mucosa. Int J Pharm 173: 193-202
<https://doi.org/10.1016/S0378-5173(98)00232-4>
29. C, Beyli M, Ferreiro MC, Ficarra G, Gill Y, Griffiths M, Holmstrup P, Mutlu S, Porter S, Wray D 1998: Update on oral lichen planus: etiopathogenesis and management. Crit Rev Oral Biol Med 9: 86-122
<https://doi.org/10.1177/10454411980090010501>
30. M, Vrhovnik K, Kristl J 1999: Liposomes as a topical delivery system: the role of size on transport studied by the EPR imaging method. J Control Release 59: 87-97
<https://doi.org/10.1016/S0168-3659(98)00181-3>
31. DH, Phil D 1975: Corticosteroid therapy. J Am Med Assoc 232: 944-948
<https://doi.org/10.1001/jama.1975.03250090034016>
32. SJ, Holbrook WP 1993: Oral mucosal adhesive ointment containing liposomal corticosteroid. Int J Pharm 95: 105-109
<https://doi.org/10.1016/0378-5173(93)90396-W>
33. Ten Cate AR 1998: Oral histology: development, structure, and function. St. Louis: Mosby Year Book, pp. 345-385
34. YT 2003: The role of acquired immunity and periodontal disease progression. Crit Res Oral Biol Med 14: 237-252
<https://doi.org/10.1177/154411130301400402>
35. DN, Ferguson MM 1994: Topical corticosteroids and lesions of the oral mucosa. Adv Drug Delivery Rev 13: 135-149
<https://doi.org/10.1016/0169-409X(94)90030-2>
36. SD, Baker KA, Williams TP 1990: Oral lichen planus: the clinical, historical, and therapeutic features of 100 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 70: 165-171
<https://doi.org/10.1016/0030-4220(90)90112-6>

